Atypical fibroxanthoma/pleomorphic dermal sarcoma of the scalp with aberrant expression of HMB-45: a pitfall in dermatopathology
Piras, Viviana
First
Writing - Original Draft Preparation
;Ferreli, CaterinaSecond
Writing - Original Draft Preparation
;Atzori, LauraMember of the Collaboration Group
;Pinna, GiampietroPenultimate
Member of the Collaboration Group
;Pilloni, LucaLast
Writing - Review & Editing
2020-01-01
Abstract
Atypical fibroxanthoma (AFX) has been considered as the non-infiltrating precursor lesion of pleomorphic dermal sarcoma (PDS), which shows an aggressive clinical behavior, because of its extensive invasion of the deeper skin layers. Although these two tumors may represent two stages of the same disease, it can be difficult to differentiate between them, because of their similar clinical and histological features 1. Furthermore, they must be distinguished from a spindled variant of squamous carcinoma, melanoma and leiomyosarcoma 2. AFX/PDS still remains a diagnosis of exclusion, that needs to combine immunohistochemical markers for a definitive diagnosis. Usually AFX/PDS shows positivity for CD10, CD99, CD68, vimentin and lysozyme, while S100, HMB45, MART-1, cytokeratins, CD34, CD31, desmin and h-caldesmon are absent.File | Size | Format | |
---|---|---|---|
FIBROXANTOMA ABERRANT.pdf open access
Type: versione editoriale
Size 306.35 kB
Format Adobe PDF
|
306.35 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.